Bleomycin‐induced pulmonary toxicity and treatment with infliximab: A case report

Given the current understanding of bleomycin‐induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF‐α) inhibitors such as infliximab for late‐stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.

Detalles Bibliográficos
Autores principales: Ge, Victor, Banakh, Iouri, Tiruvoipati, Ravindranath, Haji, Kavi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186889/
https://www.ncbi.nlm.nih.gov/pubmed/30349718
http://dx.doi.org/10.1002/ccr3.1790
_version_ 1783362926694891520
author Ge, Victor
Banakh, Iouri
Tiruvoipati, Ravindranath
Haji, Kavi
author_facet Ge, Victor
Banakh, Iouri
Tiruvoipati, Ravindranath
Haji, Kavi
author_sort Ge, Victor
collection PubMed
description Given the current understanding of bleomycin‐induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF‐α) inhibitors such as infliximab for late‐stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.
format Online
Article
Text
id pubmed-6186889
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61868892018-10-22 Bleomycin‐induced pulmonary toxicity and treatment with infliximab: A case report Ge, Victor Banakh, Iouri Tiruvoipati, Ravindranath Haji, Kavi Clin Case Rep Case Reports Given the current understanding of bleomycin‐induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF‐α) inhibitors such as infliximab for late‐stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required. John Wiley and Sons Inc. 2018-09-04 /pmc/articles/PMC6186889/ /pubmed/30349718 http://dx.doi.org/10.1002/ccr3.1790 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Ge, Victor
Banakh, Iouri
Tiruvoipati, Ravindranath
Haji, Kavi
Bleomycin‐induced pulmonary toxicity and treatment with infliximab: A case report
title Bleomycin‐induced pulmonary toxicity and treatment with infliximab: A case report
title_full Bleomycin‐induced pulmonary toxicity and treatment with infliximab: A case report
title_fullStr Bleomycin‐induced pulmonary toxicity and treatment with infliximab: A case report
title_full_unstemmed Bleomycin‐induced pulmonary toxicity and treatment with infliximab: A case report
title_short Bleomycin‐induced pulmonary toxicity and treatment with infliximab: A case report
title_sort bleomycin‐induced pulmonary toxicity and treatment with infliximab: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186889/
https://www.ncbi.nlm.nih.gov/pubmed/30349718
http://dx.doi.org/10.1002/ccr3.1790
work_keys_str_mv AT gevictor bleomycininducedpulmonarytoxicityandtreatmentwithinfliximabacasereport
AT banakhiouri bleomycininducedpulmonarytoxicityandtreatmentwithinfliximabacasereport
AT tiruvoipatiravindranath bleomycininducedpulmonarytoxicityandtreatmentwithinfliximabacasereport
AT hajikavi bleomycininducedpulmonarytoxicityandtreatmentwithinfliximabacasereport

Ejemplares similares